Latest market price analysis of deuterated colexitinib in 2025

Deucravacitinib is a selective inhibitor of tyrosine kinase 2 (TYK2), which is mainly used to treat adult patients with moderate to severe plaque psoriasis. These patients are suitable for systemic treatment or phototherapy. Deuterated coxitinib helps reduce the inflammatory response by inhibiting the activity of TYK2, thereby improving skin condition and alleviating symptoms. In recent years, with the increasing demand for the treatment of autoimmune diseases, the application prospects of this drug have become increasingly broad.

In terms of market, the original product of deuterated colexitinib has been launched in China and is included in medical insurance, allowing patients to obtain treatment at a relatively low cost. According to the latest data, the price of deuterated colexitinib's 6 mg 7-tablet package is about more than 1,000 yuan, while the price of the original research version of 6 mg 30 tablets is as high as about 50,000 yuan. Price fluctuations will be affected by exchange rates. In addition, due to the introduction of generic drugs, countries such as Laos and Bangladesh also have officially marketed generic versions of deuterated colexitinib. The price is relatively cheap. 6mg*30 tablets may be sold for about four to five hundred yuan, which provides patients with more choices.

Market analysis shows that with the increasing popularity of biologics and targeted therapies in the management of psoriasis, deuterated colexitinib, as a new treatment option, is expected to occupy an increasingly important position in the next few years, especially among patients with moderate to severe psoriasis. Its safety, effectiveness and relatively few side effects make it a preferred choice for doctors and patients. At the same time, with the continuous improvement of medical insurance policies and the improvement of patients' medication awareness, the market demand for deuterated colexitinib is expected to further grow.

In summary, deuterated colexitinib, as a new type of TYK2 inhibitor, is gradually changing the treatment landscape of moderate to severe plaque psoriasis with its unique mechanism and clinical advantages. Although original drugs are more expensive, the emergence of generic drugs provides patients with a less burdensome option, which will undoubtedly promote their widespread application and acceptance in the market.

Reference materials:https://go.drugbank.com/drugs/DB16650